Previous 10 | Next 10 |
Scientific Experts Join Atara Management Team to Discuss Role of EBV in MS and Clinical Development of ATA188 Live Conference Call and Webcast on March 22 at 4:00 p.m. EDT Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging it...
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President...
The following slide deck was published by Atara Biotherapeutics, Inc. in conjunction with their 2021 Q4 earnings call. For further details see: Atara Biotherapeutics, Inc. 2021 Q4 - Results - Earnings Call Presentation
Atara Biotherapeutics, Inc. (ATRA) Q4 2021 Earnings Conference Call February 28, 2022 04:30 PM ET Company Participants Eric Hyllengren - VP of IR and Finance Pascal Touchon - President and CEO Jakob Dupont - EVP and Global Head of Research and Development AJ Joshi - Chief Medical Officer Conf...
Atara Biotherapeutics press release (NASDAQ:ATRA): Q4 GAAP EPS of -$0.96 misses by $0.37. Revenue of $7.55M misses by $27.59M. For further details see: Atara Biotherapeutics GAAP EPS of -$0.96 misses by $0.37, revenue of $7.55M misses by $27.59M
Tab-cel U.S. BLA Submission Not Currently Expected for Q2 2022 as Further FDA Engagement and Alignment Required; Anticipated EU Approval On-Track for Q4 2022 Under Accelerated Assessment ATA188 Granted FDA Fast Track Designation in Both Non-Active PPMS and Non-Active SPMS with...
ACAD,ACHC,AGM,AMBA,AMRC,OTCPK:AOIFF,APLS,APPF,APTS,ARCT,ARDX,ASXC,ATRA,AVIR,AY,BANX,BIGC,BLFS,BLNK,BRMK,CAPL,CLDX,CO,CSR,CSTL,DAR,DDD,DNMR,DVAX,ENDP,EVA,FATE,FGEN,FRPT,FSK,GAIA,GDRX,GMRE,GOEV,GPOR,GRPN,HHC,HPQ,HRTX,ICAD,KD,LAZR,LCID,MBI,MDXG,MRTX,NKTR,NMFC,NVAX,NVEE,OCUL,OKE,ONTF,OTIC,PDCE,PG...
Atara Biotherapeutics (NASDAQ:ATRA) is scheduled to announce Q4 earnings results on Monday, February 28th, after market close. The consensus EPS Estimate is -$0.69 (+27.4% Y/Y) and the consensus Revenue Estimate is $35.14M Over the last 3 months, EPS estimates have seen 3 upward revisions and...
Atara's EBV+PTLD program got delayed by over a year. Its MS program shows early signs of promise. A patient death in an early CART program crashed the stock. For further details see: Atara Biotherapeutics: Early Stage Promises, Late Stage Delays
Palm Beach, FL –– February 24, 2022 – FinancialNewsMedia.com News Commentary – The prevalence of mental health disorders has risen exponentially but the development of novel medications has not kept pace, precipitating a crisis in psychiatric me...
News, Short Squeeze, Breakout and More Instantly...
Atara Biotherapeutics Inc. Company Name:
ATRA Stock Symbol:
NASDAQ Market:
Atara Biotherapeutics Inc. Website:
Prescription Drug User Fee Act (PDUFA) Target Action Date of January 15, 2025 If Approved, Tab-cel Would Be First Approved Therapy in U.S. for EBV+ PTLD BLA Acceptance Triggers $20 Million Milestone Payment from Pierre Fabre Laboratories, with Additional $60 Million Milestone if A...
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief E...
2024-06-27 22:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...